Rajani Dinavahi, MD, Appointed Chief Medical Officer of Ardelyx

Ardelyx (Nasdaq: ARDX) announced the appointment of Rajani Dinavahi, MD as Chief Medical Officer effective April 1, 2026.

Rhea-AI Summary

Ardelyx (Nasdaq: ARDX) announced the appointment of Rajani Dinavahi, MD as Chief Medical Officer effective April 1, 2026. Dr. Dinavahi brings more than two decades of clinical and development experience across immuno-oncology, autoimmune, metabolic disease, nephrology and transplantation.

Her background includes senior leadership at Atara Biotherapeutics and prior roles at Amgen, with experience advancing programs from early development through Phase 3 and regulatory approval.

Positive

• Appointment effective April 1, 2026
• 20+ years of clinical and biotech experience
• Led global development for an approved allogeneic T-cell therapy
• Broad therapeutic expertise: immuno-oncology, autoimmune, metabolic, nephrology, transplantation
• Senior leadership experience at Atara and program work at Amgen

Negative

• None.

Argus Apr 1 session

+2.00% close to close Open Argus

Details

News Market Reaction – ARDX

On Apr 1, the day this news came out, ARDX closed 2.00% above the previous close.

Data tracked by StockTitan Argus for the Apr 1 session.

Market Context

This announcement highlights a leadership upgrade, bringing deep experience in immuno-oncology, neph...

Analysis

This announcement highlights a leadership upgrade, bringing deep experience in immuno-oncology, nephrology and late-stage development to Ardelyx. Against a backdrop of strong 2025 revenue of $407.3M, growing IBSRELA and XPHOZAH franchises, and active investor engagement, the new CMO role aligns with a focus on pipeline execution. Investors may watch for how this hire shapes future clinical strategy, regulatory interactions and the progression of ongoing and planned trials.

Key Figures

Total revenue: $407.3M IBSRELA revenue: $274.2M XPHOZAH revenue: $103.6M +5 more

Total revenue

$407.3M

Full year 2025 total revenue

IBSRELA revenue

$274.2M

Full year 2025 IBSRELA revenue (73% YoY)

XPHOZAH revenue

$103.6M

Full year 2025 XPHOZAH revenue

Cash & short-term investments

$264.7M

Balance as of Dec 31, 2025

IBSRELA 2026 guidance

$410–$430M

Management 2026 IBSRELA revenue guidance range

XPHOZAH 2026 guidance

$110–$120M

Management 2026 XPHOZAH revenue guidance range

Net loss

$61.6M

Full year 2025 net loss

Short interest

9.18%

Short interest as percent of float; days to cover 7.49

Historical Context

5 past events · Latest: Mar 12

5 events

1. Mar 12

   Patient advocacy award

   24h Move

   -5.5%

   Recognition of five chronic kidney disease advocates with company-sponsored award.

2. Mar 09

   Clinical review data

   24h Move

   -0.8%

   Peer‑reviewed analysis showing rapid, sustained IBS‑C symptom relief with tenapanor.

3. Mar 04

   Investor conferences

   24h Move

   +6.9%

   Planned presentations and 1x1 meetings at major Miami healthcare investor events.

4. Feb 24

   LPGA partnership

   24h Move

   +14.1%

   Multi‑year LPGA collaboration to raise awareness of IBS‑C and digestive health.

5. Feb 19

   Earnings and guidance

   24h Move

   -15.0%

   2025 results, strong IBSRELA and XPHOZAH sales, 2026 revenue guidance and net loss.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

immuno-oncology, nephrology, allogeneic T-cell therapy, T-cell directed therapy, +1 more

5 terms

immuno-oncology medical

"She has extensive experience across immuno-oncology, autoimmune diseases, metabolic disease..."

Immuno-oncology is a field of medicine focused on using the body's immune system to fight cancer. It involves developing treatments that help the immune system recognize and attack cancer cells more effectively. For investors, advancements in immuno-oncology can signal promising new therapies that may lead to improved patient outcomes and potentially significant commercial opportunities.

nephrology medical

"She is board-certified in Internal Medicine and Nephrology, a Fellow of the American Society..."

Nephrology is the branch of medicine that diagnoses and treats kidney function and diseases, including conditions that affect the body’s natural ‘filtering’ system. For investors, nephrology matters because treatments, drugs, devices, and services for kidney disease represent a significant and growing market; outcomes, regulatory approvals, and changes in treatment standards can directly affect revenue, costs, and valuation for companies involved in healthcare, pharmaceuticals, and medical technology.

allogeneic T-cell therapy medical

"to deliver on the first allogeneic T-cell therapy to be approved and launched globally."

A therapy that uses immune cells (T cells) taken from a donor rather than from the patient, engineered or selected to fight disease and given to many different patients like an off‑the‑shelf medicine. Investors care because donor-based products can be made in larger batches, potentially lowering cost and speeding availability, but they also carry risks such as immune rejection, complex manufacturing and strict regulation that affect development time, pricing and market size.

T-cell directed therapy medical

"development and medical affairs of their lead T-cell directed therapy asset and allo-CART program."

T-cell directed therapy uses a patient’s own immune cells called T cells, or drugs that steer those cells, to find and destroy diseased cells such as cancer or infected tissue. Think of it like training or guiding guard dogs to sniff out and remove a specific intruder; when it works it can produce dramatic clinical benefit but development, manufacturing and safety challenges, as well as high treatment costs, make outcomes and commercial success riskier for investors.

translational immunology medical

"post-doctoral fellowship focusing on translational immunology at Mount Sinai Hospital..."

Translational immunology is the branch of biomedical research that takes discoveries about the immune system and turns them into practical tests, treatments or vaccines. For investors it signals the gap between a lab idea and a marketable product—like converting a blueprint into a working prototype—so progress in translational immunology can raise a project's chances of clinical success, shorten development time and reduce investment risk.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WALTHAM, Mass., April 01, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced the appointment of Rajani Dinavahi, MD, as Chief Medical Officer (CMO). Dr. Dinavahi brings more than two decades of experience in healthcare and biotechnology, spanning multiple therapeutic areas and modalities. She has extensive experience across immuno-oncology, autoimmune diseases, metabolic disease, nephrology and transplantation, with a track record of advancing programs from early development through Phase 3 and regulatory approval. Dr. Dinavahi most recently served as Senior Vice President, Chief Medical Officer at Atara Biotherapeutics.

“I am delighted to welcome Rajani as our new Chief Medical Officer. She brings a rare combination of scientific rigor, clinical expertise and proven leadership in advancing innovative therapies from development to patients,” said Mike Raab, president and chief executive officer of Ardelyx. “As we enter an important phase of growth and execution, Rajani’s experience and vision will be instrumental in strengthening our pipeline, deepening our medical capabilities, and ensuring we continue to deliver meaningful outcomes for patients. I look forward to partnering closely with her as we build on our momentum and shape the next chapter of our company.”

“I am thrilled to join Ardelyx at such a pivotal time in its evolution,” said Dr. Dinavahi. “The company’s commitment to advancing innovative therapies and its focus on patients strongly align with my own values and experience. I’ve been deeply impressed by the strength of the science, the dedication of the team and the opportunity to meaningfully impact patients’ lives. I look forward to working alongside this talented organization to advance the pipeline, build on the company’s momentum and help deliver important new medicines to patients who need them.”

As Chief Medical Officer at Atara Biotherapeutics, Dr. Dinavahi’s responsibilities spanned leading pre-clinical and translational sciences through global development and medical affairs of their lead T-cell directed therapy asset and allo-CART program. Prior to becoming CMO, Dr. Dinavahi held senior leadership positions at Atara across clinical sciences, program team leadership and medical affairs, where she built and led global teams to deliver on the first allogeneic T-cell therapy to be approved and launched globally. Earlier, she spent seven years at Amgen, contributing to multiple global development programs and regulatory filings for products approved across the U.S., Europe and Japan.

Dr. Dinavahi began her career in academic medicine as an Assistant Professor of Medicine (Nephrology) at Mount Sinai School of Medicine and a principal investigator in transplant research. She is board-certified in Internal Medicine and Nephrology, a Fellow of the American Society of Nephrology, and has authored numerous scientific publications and presentations. She earned a Bachelor of Science and Doctor of Medicine from the University of Miami and completed her Internal Medicine residency and Nephrology fellowship training at Thomas Jefferson University Hospital, followed by a clinical transplant and post-doctoral fellowship focusing on translational immunology at Mount Sinai Hospital in New York City.

About Ardelyx
Ardelyx is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA^® (tenapanor) and XPHOZAH^® (tenapanor). The company’s pipeline includes the Phase 3 development of tenapanor for chronic idiopathic constipation, and RDX10531, a next-generation NHE3 inhibitor with potential application across multiple therapeutic areas. Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL^® (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been approved in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. For more information, please visit https://ardelyx.com/ and connect with us on X (formerly known as Twitter), LinkedIn and Facebook.

Investor Contact:
Lisa Caperelli
lcaperelli@ardelyx.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Who is Rajani Dinavahi and what role did she assume at Ardelyx (ARDX) on April 1, 2026?

She is a physician-scientist appointed as Chief Medical Officer at Ardelyx on April 1, 2026. According to Ardelyx, she has over two decades of experience across clinical development and medical affairs, joining from Atara Biotherapeutics where she led global development efforts.

What relevant experience does CMO Rajani Dinavahi bring to Ardelyx (ARDX)?

She brings experience advancing programs from early development through Phase 3 and approval. According to Ardelyx, her background includes leading preclinical to global medical affairs and contributing to regulatory filings at Amgen.

How might Rajani Dinavahi’s appointment impact Ardelyx’s clinical pipeline and development strategy (ARDX)?

Her appointment could strengthen medical leadership and program execution at Ardelyx. According to Ardelyx, she has a track record of building global teams and advancing therapies toward regulatory approval and commercial launch.

What prior achievements at Atara Biotherapeutics are noted for Rajani Dinavahi in the Ardelyx (ARDX) announcement?

She led global development and medical affairs for Atara’s lead T-cell directed therapy and allo-CART program. According to Ardelyx, she helped deliver the first allogeneic T-cell therapy to be approved and launched globally.

What are Rajani Dinavahi’s academic and clinical qualifications noted in the Ardelyx (ARDX) release?

She holds an MD and completed residency and fellowships in nephrology and transplant immunology. According to Ardelyx, she is board-certified in Internal Medicine and Nephrology and is a Fellow of the American Society of Nephrology.